8 / 13
Page 32
conferenceseries
.com
Volume 10
Journal of Cancer Science & Therapy
Oncologists 2018
May 24-25, 2018
May 24-25, 2018 Osaka, Japan
22
nd
Global Annual Oncologists Meeting
Meta-analysis of promoter methylation in eight tumor-suppressor genes and its association with the
risk of thyroid cancer
Fatemeh Khatami
1
, Bagher Larijani
1
, Ramin Heshmat
1
, Abbasali Keshtkar
1
, Mahsa Mohammadamoli
1
, Ladan Teimoori-Toolabi
2
, Shirzad Nasiri
1
and
Seyed Mohammad Tavangar
1
1
Tehran University of Medical Sciences, Iran
2
Pasteur Institute of Iran, Iran
P
romoter methylation in a number of Tumor-Suppressor Genes (TSGs) can play crucial roles in the development of thyroid
carcinogenesis. The focus of the current meta-analysis was to determine the impact of promoter methylation of eight
selected candidate TSGs on thyroid cancer and to identify the most important molecules in this carcinogenesis pathway. A
comprehensive search was performed using Pub Med, Scopus and ISI Web of Knowledge databases and eligible studies were
included. The methodological quality of the included studies was evaluated according to the Newcastle Ottawa scale table and
pooled Odds Ratios (ORs); 95% Confidence Intervals (CIs) were used to estimate the strength of the associations with Stata
12.0 software. Egger’s and Begg’s tests were applied to detect publication bias, in addition to the Metatrimmethod. A total of 55
articles were selected and 135 genes with altered promoter methylation were found. Finally, we included eight TSGs that were
found in more than four studies (RASSF1, TSHR, PTEN, SLC5A, DAPK, P16, RARβ2 and CDH1). The order of the pooled
ORs for these eight TSGs from more to less significant was CDH1 (OR=6.73), SLC5 (OR=6.15), RASSF1 (OR=4.16), PTEN
(OR=3.61), DAPK (OR=3.51), P16 (OR=3.31), TSHR (OR=2.93) and RARβ2 (OR=1.50). Analyses of publication bias and
sensitivity confirmed that there was very little bias. Thus, our findings showed that CDH1 and SCL5A8 genes were associated
with the risk of thyroid tumor genesis.
Tavangar@ams.ac.irJ Cancer Sci Ther 2018, Volume 10
DOI: 10.4172/1948-5956-C3-130